HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)

South Korea · Delayed Price · Currency is KRW

2,400.00

+45.00 (1.91%)

Aug 12, 2026, 3:30 PM KST

-28.21% (1Y)

Market Cap	218.00B -26.0%
Revenue (ttm)	67.56B +18.1%
Net Income	-9.09B
EPS	-103.11
Shares Out	92.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	322,934
Open	2,340.00
Previous Close	2,355.00
Day's Range	2,280.00 - 2,445.00
52-Week Range	1,342.00 - 4,160.00
Beta	-0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About HLB Therapeutics

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 49

Stock Exchange KOSDAQ

Ticker Symbol 115450

Full Company Profile

Financial Performance

In 2025, HLB Therapeutics's revenue was 69.56 billion, an increase of 26.63% compared to the previous year's 54.93 billion. Losses were -9.23 billion, -59.52% less than in 2024.

Financial Statements